Participation of clinical pharmacists in patient of diffuse alveolar hemorrhage induced by human granulocyte colony-stimulating factor
10.12206/j.issn.2097-2024.202506021
- VernacularTitle:临床药师参与人粒细胞刺激因子致弥漫性肺泡出血的病例分析
- Author:
Zhihui YANG
1
;
Huadan CAI
1
;
Fangchu XU
1
;
Yuan LIU
1
;
Hailong YUAN
1
Author Information
1. Department of Pharmacy, Air Force Medical Center, Air Force Medical University, Beijing 100142, China.
- Publication Type:Medicine&Clinical
- Keywords:
human granulocyte colony-stimulating factor;
diffuse alveolar hemorrhage;
adverse drug reaction
- From:
Journal of Pharmaceutical Practice and Service
2025;43(11):567-571
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the possible mechanism and drug treatment plan of diffuse alveolar hemorrhage induced by human granulocyte colony-stimulating factor injection, point out medication risks and provide reference for medical treatment and pharmaceutical care of such patients. Methods The abnormal lung conditions of a patient treated with human granulocyte colony-stimulating factor injection was found by clinical pharmacists, who participated in clinical diagnosis and treatment by analyzing of adverse drug reactions, optimization of medical treatment and pharmaceutical care. Results Diffuse alveolar hemorrhage was likely an adverse drug reaction caused by human granulocyte colony-stimulating factor injection. The physician discontinued the medication immediately and provided treatment such as oxygen inhalation, high-dose hormone shock, plasma exchange, etc. The patient’s oxygen saturation was improved, alveolar bleeding was decreased, and the condition was improved. Conclusion Clinical pharmacists participate in patients’ medication treatment, carry out pharmaceutical guardianship, and assist physicians in adjusting treatment plans, which could contribute to the effectiveness and safety of patient treatment.
